RecruitingNCT07288333
NBI-1117570 for behavioral symptoms in adults hospitalized with schizophrenia
About this title
Read the official source — NCT07288333This study evaluates the safety and effectiveness of NBI-1117570 for people with schizophrenia.
Medication studyAges 18–55Multiple countries
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1117570 for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Kazanlak and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 16, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 120
- Sponsor
- Neurocrine Biosciences
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United Kingdom, Bulgaria, Romania
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07288333
- Official title
Show the full official title
A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Kazanlak, Bulgaria · Pazardzhik, Bulgaria · Targovishte, Bulgaria
3 more locations
- Târgu Mureş, Romania
- London, United Kingdom
- Oxford, United Kingdom
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of NBI-1117570 for people with schizophrenia.
Who is behind this study?
The study sponsor is Neurocrine Biosciences, a biotech company.
Does this study involve medication?
Yes. The study involves medication, including NBI-1117570 and Placebo.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....
KarXT or placebo to prevent relapse of psychosis linked to Alzheimer’s disease